A5048704135- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- MicroRNA in disease regulation
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medical Imaging and Pathology Studies
- Pancreatic and Hepatic Oncology Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Pleural and Pulmonary Diseases
- Histone Deacetylase Inhibitors Research
- Cancer-related Molecular Pathways
- Mast cells and histamine
- Cancer Genomics and Diagnostics
- Asthma and respiratory diseases
- Occupational and environmental lung diseases
Nippon Medical School
2016-2025
Nippon Medical School Hospital
2020-2024
Kubota (Japan)
2022
Weatherford College
2022
Chiba Hokusou Hospital
2019-2021
Pulmonary Associates
2021
Juntendo University
2021
University of Occupational and Environmental Health Japan
2021
National Cancer Center Hospital East
2021
Saga University
2021
Fifteen percent of lung cancer cases occur in never-smokers and show characteristics that are molecularly clinically distinct from those smokers. Epidermal growth factor receptor (EGFR) gene mutations, which correlated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), more frequent never-smoker cancers. In this study, microRNA (miRNA) expression profiling 28 identified aberrantly expressed miRNAs, were much fewer than cancers smokers included miRNAs previously (e.g.,...
Abstract Epithelial–mesenchymal transition (EMT) has recently been recognized as a key element of cell invasion, migration, metastasis, and drug resistance in several types cancer, including non–small lung cancer (NSCLC). Our aim was to clarify microRNA (miRNA)-related mechanisms underlying EMT followed by acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) NSCLC. miRNA expression profiles were examined before after transforming β1 (TGF-β1) exposure four human...
Transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition (EMT) has been shown to be related the pathogenesis of various diseases including lung cancer. Recently, microRNAs (miRNA) have recognized as a new class genes involved in human tumorigenesis. MiR-23a/24/27a is miRNA cluster located chromosome 19p13.12, which can function an oncogene several cancers. In this study, we analyzed miR-23a/24/27a expression 10 non-small cell cancer (NSCLC) lines by real-time PCR...
BackgroundA 17-cytokine gene expression signature in noncancerous hepatic tissue from patients with metastatic hepatocellular carcinoma (HCC) was recently found to predict HCC metastasis and recurrence. We examined whether the cytokine profile of lung could capability adjacent adenocarcinoma.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved...
Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely been reported. We hereby report the case 83-year-old woman who experienced non-Aspergillus ABPM with eosinophilia pembrolizumab that had prescribed bladder Steroid monotherapy prednisone was successful and could be resumed. Through...
Gefitinib (IRESSA), an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, has antitumour activity in the advanced non-small-cell lung cancer (NSCLC) setting. However, chemotherapy-naïve patients with NSCLC, addition of gefitinib to standard chemotherapy regimens failed increase survival. These results suggest need for improved patient selection and combination rationales targeted therapies. We have identified subpopulations adenocarcinoma cell line that are naturally...
The combination of laser microdissection and two-dimensional gel electrophoresis (2-D PAGE) has been developed to perform proteomic analysis on specific populations cells in cancer tissues. However, as conventional low sensitivity silver staining was used for spot detection, the required obtain an adequate amount protein 2-D PAGE is laborious only a restricted number spots could be visualized. As consequence, this technology impractical direct clinical applications had limited impact...
Lung cancer is the most common and cause of cancer-related death in world. Nestin, a class VI intermediate filament, known to be stem cell (CSC) marker as well neuroepithelial marker. High expression levels nestin are reported several types cancers including lung, pancreatic prostate cancers. Nestin thought regulate tumor proliferation, migration, invasion CSC properties. Here, we confirmed non-small lung (NSCLC): Immunohistochemical analysis surgical specimens detected protein cytoplasm 20...
Nintedanib (BIBF1120) is a multi-targeted angiokinase inhibitor and has been evaluated in idiopathic pulmonary fibrosis advanced non-small cell lung cancer (NSCLC) patients clinical studies. In the present study, we antitumor effects of nintedanib 16 NSCLC lines tried to identify microRNA (miRNA) associated with sensitivity nintedanib. No correlations between FGFR, PDGFR VEGFR family activation were found. The difference miRNA expression profiles 5 nintedanib-sensitive nintedanib-resistant...
Although aberrant proliferation and activation of lung fibroblasts are implicated in the initiation progression idiopathic pulmonary fibrosis (IPF), underlying mechanisms not well characterized. Numerous microRNAs (miRNAs) have been this process; however, miRNAs derived from exosomes relevance such to fibroblast-to-myofibroblast differentiation understood. In study, we attempted identify exosome-derived relevant development.Using miRNA array analysis, profiled expression sera C57BL/6 mice...
Abstract Background Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR ‐mutant non‐small cell lung cancer (NSCLC). However, mechanisms acquired drug resistance to osimertinib have not as yet been clarified. Exosomes and microRNAs (miRNAs) are involved in carcinogenesis human cancers. Methods We used previously established osimertinib‐resistant HCC827 (HCC827‐OR) PC‐9 (PC‐9‐OR) cells....
BackgroundThis multicenter phase 2 trial evaluated the safety and efficacy of osimertinib platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC).Patients methodsPatients received 80 mg once daily (QD), either cisplatin 75 mg/m2 (arm A) or carboplatin (area under curve [AUC] = 5; arm B), plus pemetrexed 500 for four cycles maintenance therapy QD every 3 weeks. The primary end-points were objective response...
Abstract To ascertain the potential for histone deacetylase (HDAC) inhibitor-based treatment in non-small cell lung cancer (NSCLC), we analyzed antitumor effects of trichostatin A (TSA) and suberoylanilide hydroxamic acid (vorinostat) a panel 16 NSCLC lines via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. TSA vorinostat both displayed strong activities 50% lines, suggesting need use predictive markers to select patients receiving this treatment. There was correlation...
Patients with non-small cell lung cancer (NSCLC) EGFR mutations have shown a dramatic response to inhibitors (EGFR-TKI). T790M mutation and MET amplification been recognized as major mechanisms of acquired resistance EGFR-TKI. Therefore, recently used in NSCLC patients clinical trials. In this study, we tried identify the mechanism inhibitors. We analyzed antitumor effects two inhibitors, PHA-665752 crizotinib, 10 lines. EBC-1 cells were only that sensitive both established...
Abstract Overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is critical in combating EGFR-mutant non-small cell lung cancer (NSCLC). We tried construct a novel therapeutic strategy conquer the second-and third-generation EGFR-TKIs EGFR-positive NSCLC patients. established afatinib- and osimertinib-resistant adenocarcinoma lines. Exome sequencing, cDNA array miRNA microarray were performed using lines discover targets associated with...